EPCAM and hepatoblastoma: We identified a subgroup of hepatoblastoma patients with early-onset age (≤1.25 years) and double positive expression of membranous EpCAM and nuclear β-catenin in tumors with better chemosensitivity and better overall and native liver survival rates.